This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/drugbank/
n16http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/mixture/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/national-drug-code-directory/
n28http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/chebi/
n6http://www.rxlist.com/cgi/generic/
n12http://linked.opendata.cz/resource/drugbank/patent/
n32http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/pharmgkb/
n26http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n7http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00346
rdf:type
n3:Drug
n3:description
Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]
n3:dosage
n19:271B5CB3-363D-11E5-9242-09173F13E4C5 n19:271B5CB4-363D-11E5-9242-09173F13E4C5 n19:271B5CB5-363D-11E5-9242-09173F13E4C5 n19:271B5CB2-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11893233 # Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7682910 # Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9122046 # Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16553574 # Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11750253
n3:group
approved investigational
n3:halfLife
10 hours
n3:indication
For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
n3:manufacturer
n10:271B5CAF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n28:DB00346 n32:DB00346
dcterms:title
Alfuzosin
adms:identifier
n18:51141 n20:D01692 n21:2008 n22:DB00346 n23:2092 n24:46508512 n25:0024-4200-30 n30:PA164774795 n31:Alfuzosin
n3:mechanismOfAction
Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
n3:packager
n10:271B5CA6-363D-11E5-9242-09173F13E4C5 n10:271B5CAD-363D-11E5-9242-09173F13E4C5 n10:271B5CAE-363D-11E5-9242-09173F13E4C5 n10:271B5CAB-363D-11E5-9242-09173F13E4C5 n10:271B5CAC-363D-11E5-9242-09173F13E4C5 n10:271B5CA9-363D-11E5-9242-09173F13E4C5 n10:271B5CAA-363D-11E5-9242-09173F13E4C5 n10:271B5CA7-363D-11E5-9242-09173F13E4C5 n10:271B5CA8-363D-11E5-9242-09173F13E4C5
n3:patent
n12:2264250 n12:6149940 n12:4661491
n3:routeOfElimination
Following oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine.
n3:synonym
Alfuzosinum (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide Alfuzosin N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide Alfuzosine Alfuzosina
n3:toxicity
Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
n3:volumeOfDistribution
* 3.2 L/kg [healthy male middle-aged volunteers]
n8:hasAHFSCode
n16:92-00-00
n3:foodInteraction
Take after a meal (always the same meal), product bioavailability is reduced when taken on an empty stomach.
n3:mixture
n29:271B5CA5-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
82%-90%
n3:salt
n3:synthesisReference
Mathias Scheer, "Alfuzosin tablets and synthesis." U.S. Patent US20060062845, issued March 23, 2006.
n14:hasConcept
n15:M0137486
foaf:page
n6:uroxatral.htm n7:uro1685.shtml n26:alfuzosin.html
n3:IUPAC-Name
n4:271B5CBA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5CC0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5CBF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5CBC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5CBD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5CBE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5CB8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5CD0-363D-11E5-9242-09173F13E4C5 n4:271B5CB6-363D-11E5-9242-09173F13E4C5 n4:271B5CB9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5CB7-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:G04CA01
n3:H-Bond-Acceptor-Count
n4:271B5CC6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5CC7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5CC1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5CC2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5CC4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5CC3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5CC5-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption is 50% lower under fasting conditions
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
81403-80-7
n3:category
n3:containedIn
n11:271B5CB0-363D-11E5-9242-09173F13E4C5 n11:271B5CB1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5CCC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5CCE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5CCF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5CCB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5CCA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5CCD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5CBB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5CC8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5CC9-363D-11E5-9242-09173F13E4C5